AVGO
Broadcom
-- 219.930 TSLA
Tesla
-- 429.955 NVDA
NVIDIA
-- 136.790 PLTR
Palantir
-- 73.876 AMD
Advanced Micro Devices
-- 127.170 
NEWS
Celularity Reports Over Sevenfold Growth in Net Product Sales through Third Quarter 2024 Compared to Third Quarter 2023
Friday, 6th December at 8:00 am
• Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings
• Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023
FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings.
Friday, 6th December at 8:00 am
• Celularity filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024, and is now current with its quarterly report filings
• Reported Total Net Revenue for the Three Months and the Nine Months ending September 30, 2024, are consistent with last guidance, with significant growth over the same periods in 2023
FLORHAM PARK, N.J., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it filed its Quarterly Report on Form 10-Q for the period ended September 30, 2024. With this filing, the Company is now current on its quarterly report filings.
For the nine months ended September 30, 2024, Celularity reported total net revenues of $36.1 million, an increase of $25.4 million, or 238.6%, compared to $10.7 million for the same period last year.
For the three months ended September 30, 2024, total net revenues were $9.3 million, an increase of $5.5 million, or 145.5%, compared to $3.8 million for the same period last year.
Product sales, net, which includes direct-to-customer sales of our advanced biomaterial products, saw the largest growth, reaching $26.2 million for the nine months ended September 30, 2024, compared to $3.6 million for the same period last year, or an increase of 621.1%.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Trytosaveabit : Hope you’re feeling better! But HMMM guess I was 100% correct that you believed you would! Hehehe